Your browser doesn't support javascript.
loading
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
Meier, Juris J; Bardtrum, Lars; Cheng, Alice Y Y; Malling, Brian; Montanya, Eduard; Wagner, Lily; Pratley, Richard E.
Afiliação
  • Meier JJ; Department of Internal Medicine, Gastroenterology and Diabetology, Augusta Clinic, Bochum, Germany.
  • Bardtrum L; Novo Nordisk A/S, Søborg, Denmark.
  • Cheng AYY; Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.
  • Malling B; Novo Nordisk A/S, Søborg, Denmark.
  • Montanya E; Hospital Universitari Bellvitge-IDIBELL CIBERDEM, and University of Barcelona, Barcelona, Spain.
  • Wagner L; Novo Nordisk A/S, Søborg, Denmark.
  • Pratley RE; AdventHealth Translational Research Institute, Orlando, Florida, USA.
Diabetes Obes Metab ; 25(4): 1130-1135, 2023 04.
Article em En | MEDLINE | ID: mdl-36562481
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article